<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Mon, 09 Nov 2009 10:37:40 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Biostar Raises $3.6 Million</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</guid>
      <description><![CDATA[Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614366>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 17:26:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSPM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</link>
    </item>
    <item>
      <title>Bulls Back On Track?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</guid>
      <description><![CDATA[Good morning. With chants of &quot;Dow 10K… Dow 10K&quot; once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614255>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 16:21:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</link>
    </item>
    <item>
      <title>Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</guid>
      <description><![CDATA[Ford's 2,215 page 2007 master contract with the UAW 
1941 UAW-Ford contract<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614051>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 13:52:50 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</link>
    </item>
    <item>
      <title>Your Kind of Day?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</guid>
      <description><![CDATA[As a rule, I try not to read too terribly much into a &quot;Fed Day&quot; as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on &quot;Fed Days.&quot; But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611831>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 19:06:48 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</link>
    </item>
    <item>
      <title>The Dollar-Proof Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</guid>
      <description><![CDATA[Don't put off this important piece of the financial-planning process.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611744>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 17:31:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GLD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IEO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STPZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VEU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VSS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WIP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</link>
    </item>
    <item>
      <title>What Investors Should Look for In Today’s Fed Statement</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</guid>
      <description><![CDATA[In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605772>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 13:04:24 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BCS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ING</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</link>
    </item>
    <item>
      <title>Are Discount Brokers Shares Worth Owning?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</guid>
      <description><![CDATA[The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&amp;P gain 15%.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604683>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 01:28:03 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMTD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ETFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SCHB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</link>
    </item>
    <item>
      <title>Technology Rises And Buying Facebook</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</guid>
      <description><![CDATA[Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%.&#160;&#160; Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601987>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:54:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EBAY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</link>
    </item>
    <item>
      <title>Buffett Gets His Cheque Book Out</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601899</guid>
      <description><![CDATA[Given the slew of positive economic data Monday you might have been forgiven for expecting a decent rebound in risk assets. There was a rebound of sorts in early New York trading, with the Dow up close to 150 points at one stage.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601899>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:17:34 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BNI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">INTC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601899</link>
    </item>
    <item>
      <title>Five Ways To Ride The Commodities Bull</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601726</guid>
      <description><![CDATA[Commodity prices have faltered in the last couple of weeks, and much of the “smart money” is saying the boom is over.
Don’t believe it.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601726>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 15:21:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">VALE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601726</link>
    </item>
    <item>
      <title>Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3613879</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 6--Targacept Inc. posted its first quarterly profit in nearly three years yesterday, bolstered in large part by a $10 million milestone payment by AstraZeneca PLC. &lt;/li&gt;&lt;li&gt;Targacept, based in Piedmont Triad Research Park in Winston-Salem, is developing drugs based on nicotine research to treat diseases of the central nervous system. &lt;/li&gt;&lt;li&gt;The payment was the result of Targacept's research in adult attention deficit/hyperactivity disorder involving its AZD3480 drug compound, also known as TC-1734.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3613879>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TRGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3613879</link>
    </item>
    <item>
      <title>AstraZeneca Q3 Net Income Up</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3592781</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;AstraZeneca, a UK-based pharmaceutical company, has reported a net income of $2.12 billion, or $1.46 per diluted share, for the third quarter ended September 30, 2009, compared to $1.74 billion, or $1.19 per diluted share, for the third quarter ended September 30, 2008.&lt;/li&gt;&lt;li&gt;Net income for the nine months ended September 30, 2009 was $5.98 billion, or $4.12 per diluted share, compared to $4.88 billion, or $3.33 per share, for the nine months ended September 30, 2008. &lt;/li&gt;&lt;li&gt;Total revenues were $23.86 billion for the nine months ended September 30, 2009, compared to $23.41 billion, for the prior-year period.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3592781>[More...]</a>]]></description>
      <pubDate>Fri, 30 Oct 2009 10:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3592781</link>
    </item>
    <item>
      <title>Earnings Preview: Bristol-Myers 3Q earnings report</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3568342</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;NEW YORK - Bristol-Myers Squibb Co., the world's No. &lt;/li&gt;&lt;li&gt;The following is a summary of key developments and analyst opinion related to the period.&lt;/li&gt;&lt;li&gt;OVERVIEW: Growing competition for its top drugs threatens revenue for the maker of blood thinner Plavix, the world's second-bestselling medication, and psychiatric drug Abilify.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3568342>[More...]</a>]]></description>
      <pubDate>Wed, 21 Oct 2009 15:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3568342</link>
    </item>
    <item>
      <title>Drug makers, CVS slammed for promos</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3560042</guid>
      <description><![CDATA[Drug makers, CVS slammed for promos<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3560042>[More...]</a>]]></description>
      <pubDate>Sun, 18 Oct 2009 21:42:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3560042</link>
    </item>
    <item>
      <title>Business Highlights</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3558392</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Bank of America loses $2.24B as loan losses rise&lt;/li&gt;&lt;li&gt;CHARLOTTE, N.C. (AP) - Bank of America Corp. said Friday it lost more than $2.2 billion in the third quarter as loan losses kept rising, providing more evidence that consumers are still struggling to pay their bills.&lt;/li&gt;&lt;li&gt;The bank's total allowance for loan and lease losses now totals $35.83 billion.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3558392>[More...]</a>]]></description>
      <pubDate>Fri, 16 Oct 2009 22:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BAC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WMT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3558392</link>
    </item>
    <item>
      <title>Dampier Defends Woodford Income Strategy</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3556374</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Hargreaves Lansdown head of research Mark Dampier has defended Invesco Perpetual UK equity income guru Neil Woodford's performance, and says now is the best time to invest.&lt;/li&gt;&lt;li&gt;Woodford's pound 6.4bn income and pound 8.6bn higher-income funds are 17th and 18th respectively in the UK equity income and growth sector from January 1 to September 25, according to figures from Lipper.&lt;/li&gt;&lt;li&gt;However, Dampier says this is due to the manager's long-term, bearish economic outlook and stocks that match this view - namely those with strong balance sheets and stable business models such as AstraZeneca and GlaxoSmithKline.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3556374>[More...]</a>]]></description>
      <pubDate>Thu, 15 Oct 2009 09:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3556374</link>
    </item>
    <item>
      <title>FUND FOCUS: Down but Not Out</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3556375</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;The stockmarket rally since March has been dramatic, with the FTSE 100 up 46 per cent. &lt;/li&gt;&lt;li&gt;Probably the most high-profile of these are the popular income and high-income funds run by Neil Woodford of Invesco Perpetual. &lt;/li&gt;&lt;li&gt;You need to know what drives Mr Woodford's stock selection in order to be better placed to judge whether you agree or disagree with his investment stance.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3556375>[More...]</a>]]></description>
      <pubDate>Thu, 15 Oct 2009 09:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3556375</link>
    </item>
    <item>
      <title>ANALYSIS: Liontrust's New Contrarian Process</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3546208</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Liontrust shares dived when the popular managers of the First Income fund left in January. &lt;/li&gt;&lt;li&gt;But investors are being urged to hold on - the new managers have a novel process to implement.&lt;/li&gt;&lt;li&gt;Its two best known managers, Jeremy Lang and William Pattisson, who ran more than 80% of the company's then pound 3.5 billion under management, departed in January.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3546208>[More...]</a>]]></description>
      <pubDate>Mon, 12 Oct 2009 09:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3546208</link>
    </item>
    <item>
      <title>Daily Mail, London, Market Report Column</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3452482</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Sep. 2--It's a big month for Burberry. &lt;/li&gt;&lt;li&gt;The 153-year-old British luxury  fashion house will be showcasing its spring 2010 Prorsum collection at the  25th anniversary of London Fashion Week on September 22.  &lt;/li&gt;&lt;li&gt;But before then,  on September 9, chief executive Angela Ahrendts and the rest of her board  should be popping pink champagne corks in celebration of the group's first  admission to the elite Footsie index since floating on the London Stock  Exchange in July 2002.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3452482>[More...]</a>]]></description>
      <pubDate>Wed, 02 Sep 2009 14:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AIM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3452482</link>
    </item>
    <item>
      <title>Evening Standard, London, Market Report Column</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3450458</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Sep. 1--Drugs giant AstraZeneca was showing the rest of the top 100  companies a clean pair of heels today, spurred on by recommendations from two  of the City's biggest players. &lt;/li&gt;&lt;li&gt;UBS has a buy rating on  AZ and believes there is still scope for improvement in the shares by raising  its target from 3500p to 3600p.  &lt;/li&gt;&lt;li&gt;The group also whetted the City's appetite by claiming its new blood  thinner pill Bilinta is an improvement on the current market leader Plavix,  which is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3450458>[More...]</a>]]></description>
      <pubDate>Tue, 01 Sep 2009 21:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AIM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">C</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LII</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3450458</link>
    </item>
    <item>
      <title>Phase Forward Reports Third Quarter 2009 Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3591497</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data   management solutions for clinical trials and drug safety, today   announced its financial results for the third quarter of 2009.&lt;/li&gt;&lt;li&gt;Within total   revenues, electronic data capture (EDC) license, application hosting and   other related revenues were $38.5 million, representing 71% of third   quarter total non-GAAP revenues and an increase of 18% from $32.7   million in the prior year period.&lt;/li&gt;&lt;li&gt;Weiler added, &quot;During the third quarter, a pharmaceutical company in the   top 40 in sales selected Phase Forward's InForm EDC solution for a   multi-year, multi-million dollar commitment, while a leading provider of   information technology, consulting, and business process outsourcing   services selected InForm as part of their outsourcing services to a top   10 pharma.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3591497>[More...]</a>]]></description>
      <pubDate>Thu, 29 Oct 2009 20:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFWD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PG</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3591497</link>
    </item>
    <item>
      <title>Howard Dean to Speak at the 2009 Mid-Atlantic Bio Conference</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3590187</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Mid-Atlantic Bio today announced that former Vermont Governor Howard   Dean will serve as the closing plenary speaker at the 2009 Mid-Atlantic   Bio Conference, November 4 through 6, held in Washington, D.C., at the   Washington, DC Convention Center. &lt;/li&gt;&lt;li&gt;Additionally, Representative Charles Boustany (R-La.) &lt;/li&gt;&lt;li&gt;Mid-Atlantic Bio is co-hosted by the region's most influential   life science and investor associations, MdBio Division of the Tech   Council of Maryland (TCM/MdBio), the Mid-Atlantic Venture Association   (MAVA), and the Virginia Biotechnology Association (VaBIO).&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3590187>[More...]</a>]]></description>
      <pubDate>Thu, 29 Oct 2009 16:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3590187</link>
    </item>
    <item>
      <title>AstraZeneca: Third Quarter and Nine Months Results 2009</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3589901</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;AstraZeneca (STO:AZN) (LSE:AZN)&lt;/li&gt;&lt;li&gt;Third quarter revenue increased by 10 percent at constant exchange rates   (CER) to $8,200 million.&lt;/li&gt;&lt;li&gt;-Emerging Markets revenue was up 15 percent at CER; on track for   double-digit growth for the full year.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3589901>[More...]</a>]]></description>
      <pubDate>Thu, 29 Oct 2009 13:52:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NKTR</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3589901</link>
    </item>
    <item>
      <title>POZEN Reports Third Quarter 2009 Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3586340</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;POZEN Inc. (NASDAQ: POZN), today announced results for the   third quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;POZEN reported a net income of $6.7 million, or $0.22 per share on a   diluted basis, for the third quarter of 2009, compared to net loss of   $(7.9) million, or $(0.26) per share on a diluted basis, for the third   quarter of 2008.&lt;/li&gt;&lt;li&gt;Revenue for the third quarter ended September 30, 2008   totaled $11.1 million, resulting from the amortization of upfront   payments received pursuant to the collaboration agreements with   AstraZeneca and GlaxoSmithKline of $3.2 million, $7.5 million of revenue   for development work, and $0.4 million of royalties on sales of Treximet.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3586340>[More...]</a>]]></description>
      <pubDate>Wed, 28 Oct 2009 11:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">POZN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3586340</link>
    </item>
    <item>
      <title>Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3571548</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Bristol-Myers   Squibb Company (NYSE:BMY) today reported strong sales and earnings   growth for the third quarter 2009.&lt;/li&gt;&lt;li&gt;&quot;The performance in the third quarter of 2009 clearly shows the results   of our outstanding business performance, disciplined financial   management and overall strategic execution,&quot; said James   M. Cornelius, chairman and chief executive officer. &lt;/li&gt;&lt;li&gt;Third Quarter Performance                                                                                                                2009        2008        Change   Net Sales                                           $  5,487    $  5,254    4%       Net Earnings from Continuing Operations             $  966      $  588      64%      GAAP Diluted EPS from Continuing Operations            0.48        0.29     66%      Non-GAAP Diluted EPS from Continuing Operations        0.52        0.45     16%      ($ amounts in millions, except per share amounts)&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3571548>[More...]</a>]]></description>
      <pubDate>Thu, 22 Oct 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MJN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3571548</link>
    </item>
    <item>
      <title>Merck Announces Third-Quarter 2009 Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3571555</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Merck &amp; Co., Inc. today announced financial results for the third &lt;/li&gt;&lt;li&gt;Merck &amp; Co., Inc. Consolidated Results (In Millions Except Earnings per Common Share) Quarter Ended September 30 (Unaudited) &lt;/li&gt;&lt;li&gt;The following table shows the financial results for Merck &amp; Co., Inc.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3571555>[More...]</a>]]></description>
      <pubDate>Thu, 22 Oct 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3571555</link>
    </item>
    <item>
      <title>Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3555150</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for   the third quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;With three quarters of 2009 revenue recorded, Cubist has tightened its   full year 2009 guidance for CUBICIN U.S. net revenue to between $520 and   $525 Million, which is within the range the company announced in   January. &lt;/li&gt;&lt;li&gt;Our strong top and bottom line results have   been achieved in an environment that has been tough for many branded   pharmaceuticals.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3555150>[More...]</a>]]></description>
      <pubDate>Thu, 15 Oct 2009 20:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CBST</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3555150</link>
    </item>
    <item>
      <title>Targacept Announces Pricing of Common Stock Offering</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3538178</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Targacept, Inc. (NASDAQ:TRGT)   announced today that the recently announced underwritten public offering   of 2,200,000 shares of its common stock has been priced at a price to   the public of $21.00 per share. &lt;/li&gt;&lt;li&gt;As previously announced, Deutsche Bank   Securities will act as sole manager for the offering andTargacept has   granted Deutsche Bank Securities an option to purchase an additional   320,000 shares of common stock to cover over-allotments, if any.&lt;/li&gt;&lt;li&gt;The offering is being made pursuant to an effective shelf registration   statement that Targacept previously filed with the Securities and   Exchange Commission.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3538178>[More...]</a>]]></description>
      <pubDate>Thu, 08 Oct 2009 14:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TRGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3538178</link>
    </item>
    <item>
      <title>Targacept Announces Common Stock Offering</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3538045</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Targacept, Inc. (NASDAQ:TRGT)   announced today the pricing of an underwritten public offering of   2,200,000 shares of its common stock. &lt;/li&gt;&lt;li&gt;Deutsche Bank Securities will act   as sole manager for the offering. &lt;/li&gt;&lt;li&gt;Targacept has granted Deutsche Bank   Securities an option to purchase an additional 320,000 shares of common   stock to cover over-allotments, if any.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3538045>[More...]</a>]]></description>
      <pubDate>Thu, 08 Oct 2009 13:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TRGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3538045</link>
    </item>
    <item>
      <title>Troux Secures $10 Million to Extend Growth in New Geographies and Channels</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3537559</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Troux Technologies, Inc., the leader in Strategic   IT Planning and Control software, today announced that it has   secured a $10 million investment to further expand reach into new   geographies and extend recent sales momentum. &lt;/li&gt;&lt;li&gt;The investment follows a period of record revenues and growth for Troux.   &lt;/li&gt;&lt;li&gt;&quot;Despite the global recession, we have made significant progress in our   expansion plans, proving our ability to win business and drive customer   success in major organizations around the globe,&quot; said David Hood, chief   executive officer of Troux.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3537559>[More...]</a>]]></description>
      <pubDate>Thu, 08 Oct 2009 10:45:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3537559</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=ABBI,AZN," rel="self" type="application/rss+xml" />
  </channel>
</rss>